Free Trial

Allspring Global Investments Holdings LLC Lowers Stock Holdings in Addus HomeCare Corporation (NASDAQ:ADUS)

Addus HomeCare logo with Medical background

Allspring Global Investments Holdings LLC lessened its stake in Addus HomeCare Corporation (NASDAQ:ADUS - Free Report) by 59.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 28,307 shares of the company's stock after selling 42,031 shares during the period. Allspring Global Investments Holdings LLC owned about 0.16% of Addus HomeCare worth $2,799,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Alliancebernstein L.P. lifted its holdings in Addus HomeCare by 0.5% in the fourth quarter. Alliancebernstein L.P. now owns 19,661 shares of the company's stock valued at $2,465,000 after buying an additional 91 shares during the period. Natixis raised its position in shares of Addus HomeCare by 111.9% in the 4th quarter. Natixis now owns 250 shares of the company's stock worth $31,000 after acquiring an additional 132 shares in the last quarter. Heritage Family Offices LLP lifted its stake in shares of Addus HomeCare by 6.3% in the 1st quarter. Heritage Family Offices LLP now owns 2,417 shares of the company's stock valued at $239,000 after purchasing an additional 143 shares during the period. Stifel Financial Corp boosted its position in shares of Addus HomeCare by 1.2% during the 4th quarter. Stifel Financial Corp now owns 12,794 shares of the company's stock valued at $1,604,000 after purchasing an additional 153 shares in the last quarter. Finally, CreativeOne Wealth LLC grew its stake in Addus HomeCare by 2.6% during the fourth quarter. CreativeOne Wealth LLC now owns 6,843 shares of the company's stock worth $858,000 after purchasing an additional 175 shares during the period. Institutional investors own 95.35% of the company's stock.

Addus HomeCare Trading Up 2.1%

ADUS traded up $2.34 during midday trading on Wednesday, reaching $114.41. 145,964 shares of the company's stock traded hands, compared to its average volume of 166,059. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of 25.83, a P/E/G ratio of 1.59 and a beta of 0.81. Addus HomeCare Corporation has a 52 week low of $88.96 and a 52 week high of $136.72. The firm has a fifty day moving average of $112.17 and a two-hundred day moving average of $110.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.74 and a quick ratio of 1.74.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.42 earnings per share for the quarter, topping analysts' consensus estimates of $1.33 by $0.09. Addus HomeCare had a net margin of 6.52% and a return on equity of 9.23%. The firm had revenue of $337.71 million for the quarter, compared to the consensus estimate of $341.66 million. During the same period in the prior year, the firm earned $1.21 EPS. The company's revenue was up 20.3% compared to the same quarter last year. On average, equities analysts anticipate that Addus HomeCare Corporation will post 4.59 earnings per share for the current fiscal year.

Insider Transactions at Addus HomeCare

In other news, EVP Michael D. Wattenbarger sold 2,045 shares of Addus HomeCare stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $115.00, for a total transaction of $235,175.00. Following the transaction, the executive vice president owned 7,796 shares in the company, valued at $896,540. This trade represents a 20.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on ADUS. Wall Street Zen upgraded shares of Addus HomeCare from a "hold" rating to a "buy" rating in a report on Sunday, June 29th. Stephens reaffirmed an "overweight" rating and issued a $142.00 target price on shares of Addus HomeCare in a research report on Wednesday, March 12th. Macquarie reiterated an "outperform" rating and issued a $133.00 price target on shares of Addus HomeCare in a report on Tuesday, June 10th. Finally, JMP Securities restated a "market outperform" rating and set a $150.00 price objective on shares of Addus HomeCare in a report on Friday, June 20th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $142.57.

Get Our Latest Research Report on Addus HomeCare

About Addus HomeCare

(Free Report)

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.

Read More

Institutional Ownership by Quarter for Addus HomeCare (NASDAQ:ADUS)

Should You Invest $1,000 in Addus HomeCare Right Now?

Before you consider Addus HomeCare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Addus HomeCare wasn't on the list.

While Addus HomeCare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines